Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bioptik TechnologyROCO:4161 -0.22%69 EV-to-EBIT is 10.40 as of Sep. 02, 2026, which is 39% below its 10-year median of 17.13. GuruFocus rates ROCO:4161 with a GF Score™ of 69/100 and a GF Value™ of NT$29.77 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 473 Medical Devices & Instruments companies, Bioptik Technology ranks better than 74.21% on this metric.
The historical rank and industry rank for Bioptik Technology's EV-to-EBIT or its related term are showing as below:
ROCO:4161'
s EV-to-EBIT Range Over the Past 10 Years
Min: -366.39 Med: 17.13 Max: 895.72
Current: 10.41
During the past 13 years, the highest EV-to-EBIT of Bioptik Technology was 895.72. The lowest was -366.39. And the median was 17.13.
ROCO:4161's EV-to-EBIT is ranked better than 74.21% of 473
companies
in the Medical Devices & Instruments industry
Industry Median: 18.71
vs ROCO:4161: 10.41
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Bioptik Technology's Enterprise Value for the quarter that ended in Jun. 2026 was NT$1,411.0 Mil.
Bioptik Technology's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$134.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioptik Technology EV-to-EBIT Related Terms
Bioptik Technology EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Bioptik Technology's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Bioptik Technology's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioptik Technology EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bioptik Technology's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Bioptik Technology's EV-to-EBIT falls into.
Bioptik Technology's current Enterprise Value is NT$1,396.1 Mil.
Bioptik Technology's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$134.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioptik Technology (ROCO:4161) has a EV-to-EBIT of 10.40 as of Sep. 02, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Bioptik Technology and its competitors. This is 39% below median its historical median of 17.13. According to the industry distribution chart, Bioptik Technology ranks #122 out of 473 companies in the Medical Devices & Instruments industry, placing it in the top 25.8%.
Is Bioptik Technology's EV-to-EBIT too high?
Bioptik Technology's current EV-to-EBIT of 10.40 is 39% below median its 10-year median of 17.13. The Medical Devices & Instruments industry median EV-to-EBIT is 18.71. Bioptik Technology's value of 10.40 is 44.4% below this industry median. Based on the distribution chart, Bioptik Technology ranks #122 out of 473 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Bioptik Technology has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bioptik Technology's EV-to-EBIT compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Bioptik Technology ranks #122 out of 473 companies for EV-to-EBIT. This puts Bioptik Technology in the upper half of its industry. The industry median EV-to-EBIT is 18.71. Bioptik Technology's value of 10.40 is 44.4% below this benchmark. While the company's 10-year median is 17.13 vs. the industry median of 18.71, Bioptik Technology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.71, based on 473 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bioptik Technology's current EV-to-EBIT of 10.40 is 44.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Bioptik Technology and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioptik Technology's current EV-to-EBIT is 10.40, which is 39% below median its own 10-year median of 17.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioptik Technology stock overvalued right now?
Based on GuruFocus' analysis, Bioptik Technology (ROCO:4161) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$29.77, compared to a current price of NT$22.85 — trading 23.2% below its estimated fair value. The current EV-to-EBIT is 10.40, which is 39% below median its 10-year median of 17.13 and 44.4% below the Medical Devices & Instruments industry median of 18.71. Bioptik Technology's overall GF Score™ is 69/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Bioptik Technology (ROCO:4161), the current EV-to-EBIT is 10.40 as of Sep. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bioptik Technology (ROCO:4161) Overvalued in 2026?
Based on GuruFocus' analysis, Bioptik Technology stock appears to be undervalued.
The current stock price of NT$22.85 is trading 23.2% below its estimated GF Value™ of NT$29.77.
GuruFocus considers Bioptik Technology to be Modestly Undervalued.
Key valuation signals for ROCO:4161:
EV-to-EBIT: 10.40 (39% below median its 10-year median of 17.13)
GF Value™: NT$29.77 vs. price of NT$22.85 (23.2% below fair value)
Industry Position: 44.4% below the Medical Devices & Instruments median (#122 of 473)
No single metric tells the full story. See the ROCO:4161 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioptik Technology Inc is a Taiwan-based company engaged in the research, development, production, and sale of medical devices and reagents. The company is also focused on developing skin care products and aims to engage in developing bioenergy, Astaxanthin, and Cellulose Bioethanol. It is involved in the business areas of Home care medical devices, Skincare- Its own brand, Dietary supplement OEM and ODM, Skincare- OEM and ODM, and Biodiesel. In the Home care business area, the company provides Easy Touch blood glucose monitoring, and blood cholesterol and uric acid monitoring systems, as well as its strips.
69GF Score
Get the complete analysis for ROCO:4161
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4161 has been successfully added to your 
